BIOGRAPHICAL SKETCH. DEGREE (if applicable)

Transcription

1 BIOGRAPHICAL SKETCH NAME: Jafi Alyssa Lipson, M.D. era COMMONS USER NAME: JLIPSON POSITION TITLE: Assistant Professor (Medical Center Line) EDUCATION/TRAINING INSTITUTION AND LOCATION DEGREE (if applicable) Completion Date MM/YYYY FIELD OF STUDY Harvard College (Cambridge, MA) AB 06/95 History of Science UCSF (San Francisco, CA) MD 12/03 Medicine St. Mary s Medical Center (San Francisco, CA) Internship 06/05 Internal Medicine UCSF (San Francisco, CA) Residency 06/09 Diagnostic Radiology Stanford University (Stanford, CA) Fellowship 06/10 Breast Imaging A. Personal Statement I am an investigator and faculty member in the Stanford University School of Medicine Department of Radiology, Breast Imaging Division. My clinical work includes screening and diagnostic mammography, diagnostic breast ultrasound, screening and diagnostic breast MRI, and minimally -invasive breast biopsy and wire localization guided by x-ray, ultrasound, and MRI. My research interests include mammographic density and breast cancer risk assessment; early breast cancer detection and extent of disease evaluation using contrast enhanced mammography and MRI; novel blood and imaging biomarkers of breast cancer burden and neoadjuvant treatment response; and wireless localization strategies for non -palpable breast tumors. B. Positions and Honors Positions and Employment 2010-Present Honors Assistant Professor of Radiology, Department of Radiology, Breast Imaging Stanford University School of Medicine (Stanford, CA) Junior Faculty of the Year: Awarded by the Stanford University School of Medicine Department of Radiology UCSF NIH T32 Training Grant Recipient: Awarded for a year of research on radiation dose with CT Alpha Omega Alpha Honor Medical Society: Elected Member UCSF Curriculum Ambassador Scholarship: Awarded for work on developing a new UCSF School of Medicine curriculum Michael C. Rockefeller Memorial Fellowship: Awarded by Harvard University for a year of purposeful postgraduate travel and writing in Italy Ford Foundation Research Fellowship: Senior honors thesis research on celluloid therapy, the use of movies in the rehabilitation of amputee veterans of WWII Elizabeth Cary Agassiz & John Harvard Scholarships: Awarded by Radcliffe & Harvard Colleges for academic achievement of the highest distinction

2 C. Contribution to Science My investigative program has been focused on the following areas: breast density and risk assessment; breast imaging for oncology clinical trials; novel blood biomarkers for early cancer detection; emerging imaging strategies for extent of disease evaluation and preoperative planning; and breast imaging outcomes and quality improvement. I have developed collaborations with faculty both within the Department of Radiology and across Stanford University, including the Health Research and Policy Division of the Department of Medicine, the Informatics Division and Radiological Sciences Laboratory (RSL) of the Department of Radiology, and the Division of Oncology Cancer Genetics Clinic of the Department of Medicine. My prior research activities focused on radiation dose with CT and the associated risk of cancer. As an NIH- funded T32 Research Fellow under the mentorship of Dr. Rebecca Smith - Bindman, I conducted a study of four San Francisco Bay Area hospitals in which I reviewed 1,200 CT examinations and CT radiation dose reports; estimated the effective dose from each examination; and calculated the associated risk of cancer attributable to that effective dose. My study culminated in a 2009 Archives of Internal Medicine publication entitled "Radiation Dose Associated with Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer", one of the first articles to raise national attention regarding the issue of medical radiation and the need for clinical practice guidelines to track and reduce dose 1. In the area of breast density and breast cancer risk assessment, I have studied and published on patient awareness of breast density and interest in additional screening tests for women with dense breasts. Based on surveys of patients of both high and low socioeconomic status in both academic and county facilities, my work presented at the 2012 and 2013 RSNA Annual Meetings and published in the Journal of the American College of Radiology (a) revealed the potential for disparity in health care access for women of lower socioeconomic status after the enactment of breast density notification legislation. I served as lead author of a website ( launched in April 2013, with online resources for patients and clinicians developed by the California Breast Density Information Group (CBDIG), a working group of breast radiologists and breast cancer risk specialists in response to breast density notification legislation in California (SB 1538). From 4/1/2013 9/28/2015, there have been 52,499 visitors to the website (86% new, 14% returning) from over 10 countries including the US, Canada, UK, Brazil, Australia, Germany, India, New Zealand, Philippines, and Japan. The website is a featured patient information resource on the ACR website and has also been adapted with permission by University of North Carolina, North Carolina Radiological Society, Massachusetts Radiological Society, Barbara Brodsky Comprehensive Breast Center (BBCBC) at Bryn Mawr Hospital in Pennsylvania, Michigan Cancer Consortium, Radiological Society of New Jersey, and the Oregon Breast and Cervical Cancer Program, for use in response to the passage of legislation in their respective states. I also served as corresponding author on a publication in Radiology which details the multi-institutional and multidisciplinary approach of the CBDIG and offers a framework for responses to similar legislation passed across the United States (b). Most recently, I have served as coinvestigator on an NIH R01-funded study of the genetics of mammographic breast density and breast cancer risk in a Kaiser cohort, in which my role is to facilitate the quantitative estimation of mammographic density on 30,000 mammograms.

3 a) Trinh L, Ikeda DM, Miyake KK, Trinh J, Lee KK, Dave H, Hanafusa K, Lipson J. Patient awareness of breast density and interest in supplemental screening tests: comparison of an academic facility and a county hospital. J Am Coll Radiol Mar;12(3): doi: /j.jacr Epub 2014 Nov 4. PubMed PMID: b) Price ER, Hargreaves J, Lipson JA, Sickles EA, Brenner RJ, Lindfors KK, Joe BN, Leung JW, Feig SA, Bassett LW, Ojeda-Fournier H, Daniel BL, Kurian AW, Love E, Ryan L, Walgenbach DD, Ikeda DM. The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. Radiology Dec;269(3): doi: /radiol Epub 2013 Oct 28. PubMed PMID: I have been a contributing investigator and primary interpreting radiologist for several breast oncology clinical trials, performing breast MRI tumor measurements and evaluating qualitative and quantitative patterns of response for a phase II study of a novel PARP inhibitor in the neoadjuvant treatment of triple negative and BRCA-associated breast cancer (a); making mammographic density measurements for a clinical trial of Lovastatin for modification of biomarkers associated with breast cancer risk (b) and making mammographic density measurements for a retrospective study of breast cancer risk factors among a cohort of Asian and Caucasian BRCA 1/2 mutation carriers (c). a) Golden DI, Lipson JA, Telli ML, Ford JM, Rubin DL. Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. J Am Med Inform Assoc Nov-Dec;20(6): doi: /amiajnl Epub 2013 Jun 19. PubMed PMID: ; PubMed Central PMCID: PMC b) Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat Nov;142(2): doi: /s z. Epub 2013 Oct 29. PubMed PMID: c) de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Fam Cancer Sep;11(3): doi: /s PubMed PMID: In the area of novel blood-based biomarkers for early breast cancer detection, I serve as co-pi and co- investigator on several protocols aimed at improving the discrimination between benign and malignant breast lesions, as well as indolent and aggressive malignant breast lesions. In collaboration with researchers at the Canary Center at Stanford for Cancer Early Detection, I provide clinical expertise and facilitate access to patient imaging, blood, and tissue specimens for correlative studies. 4. In the area of emerging imaging strategies for extent of disease evaluation and preoperative planning, I am Principal Investigator on a prospective clinical trial comparing contrast -enhanced digital mammography to contrast-enhanced MRI for the evaluation of patients with known breast cancer: Contrast-Enhanced Digital Mammography(CEDM) vs

4 Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer NCT ; and I am co- Investigator on a clinical evaluation of axillary lymph node tattooing in patients undergoing percutaneous biopsy for breast cancer staging (a). The goal of these trials is to build the evidence base for accessible, better tolerated, and cost-effective imaging-guided techniques in the pre- operative evaluation of breast cancer patients. a) Choy N, Lipson J, Porter C, Ozawa M, Kieryn A, Pal S, Kao J, Trinh L, Wheeler A, Ikeda D, Jensen K, Allison K, Wapnir I. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol Feb;22(2): doi: /s Epub 2014 Aug 28. PubMed PMID: I have also led and participated in several retrospective breast imaging studies that seek to evaluate patient outcomes and identify quality improvement opportunities. A project focused on adherence, cost, and utility considerations of imaging follow-up after benign concordant image-guided breast biopsy was awarded an RSNA Trainee Prize (November 2012). A project on compliance with recommended follow-up after MRI-guided core needle biopsy of suspicious breast lesions revealed predictors of patient noncompliance and highlighted strategies to improve follow-up with patient education (a) A group Practice Quality Improvement (PQI) project on mammographic positioning to evaluate the impact of inadequate positioning on our institutional recall rate has helped to identify group and tailored interventions to address this technical hurdle. a) Thompson MO, Lipson J, Daniel B, Harrigal C, Mullarkey P, Pal S, Thompson AC, Ikeda D. Why are patients noncompliant with follow-up recommendations after MRI-guided core needle biopsy of suspicious breast lesions? AJR Am J Roentgenol Dec;201(6): doi: /AJR PubMed PMID: Complete List of Published Work in MyBibliography: ort=date&direction=ascending D. Research Support Active Support: Hologic, Inc (Lipson, JA) 01/01/14-12/31/16 Contrast Enhanced Digital Mammography (CEDM) vs. Contrast Enhanced Breast MRI (CE- MRI) in Patients with Known Breast Cancer (BI-RADS 6) To determine how accurately one can estimate the size of the index tumor and extent of disease on preoperative contrast enhanced digital mammography and contrast enhanced breast MRI in patients with known breast cancer, using pathology as a reference standard. R01 CA A1 (Weiva, Sieh) 08/01/12-05/31/16 NIH Genetics of Mammographic breast density and breast cancer risk in a Kaiser cohort. To facilitate the quantitative estimation of mammographic density on 30,000 mammograms and the identification of genetic underpinnings of the association between mammographic density and breast cancer risk.

5 CDMRP BC (Pitteri/Oakley-Girvan) 10/01/15-09/30/18 DOD Distinguishing Benign from Malignant Breast Lesions: Does Breast Interstitial Fluid Hold the Answers? To collect interstitial fluid from women with suspicious breast lesions, develop a microchip sensor to measure levels of S100A4, and to measure levels of proteins in interstitial fluid to identify malignant lesions. Completed Support: Stanford University Department of Radiology (Lipson/ Pitteri) 09/01/12-12/31/13 A Pilot Study of Correlative Imaging, Leukocyte Telomere Length, and Circulating Telomerase Levels of Patients with Benign and Malignant Breast Lesions To evaluate whether the combination of imaging and novel blood biomarkers improve the discrimination of benign and malignant breast lesions. BiPar Sciences/Sanofi-Aventis (Kurian/Telli) 07/01/10-06/30/15 A Phase II Study of Gemcitabine, Carboplatin and Poly (ADP) Ribose Polymerase (PARP) Inhibitor BSI-201 in the Neoadjuvant Treatment of Triple-Negative and BRCA-associated Breast Cancer To evaluate qualitative and quantitative patterns of response to neoadjuvant PARP inhibitor therapy using dynamic contrast-enhanced breast MRI, and correlative histology and genomic findings. Stanford Cancer Institute 01/01/15-12/31/15 Novel Image Features on Screening Mammography and Breast Cancer Risk Prediction To assemble mammograms and covariate data for healthy women who do and do not go on to develop breast cancer, develop automated methods to measure novel morphologic and textural features of breast tissue composition on raw and processed digital mammograms, and identify novel image features that predict breast cancer risk using machine learning methods.